Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick W K Tam

Showing results (1-10 of 87) with videos related to

Pageof 9
Sort By:
Expert Opinion on Investigational Drugs|October 17, 2006
Current pharmacotherapy for the treatment of crescentic glomerulonephritisFrederick W K Tam
Seminars in Nephrology|September 5, 2018
Role of the Spleen Tyrosine Kinase Pathway in Driving Inflammation in IgA NephropathyStephen McAdoo, Frederick W K Tam
Clinica Chimica Acta; International Journal of Clinical Chemistry|August 20, 2011
Urinary monocyte chemoattractant protein-1 in renal diseaseMin Jeong Kim, Frederick W K Tam
Drugs of the Future|January 4, 2013
Fostamatinib DisodiumStephen P McAdoo, Frederick W K Tam
Clinical Journal of the American Society of Nephrology : CJASN|December 15, 2017
TESTING Corticosteroids in IgA Nephropathy: A Continuing ChallengeFrederick W K Tam, Charles D Pusey
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 16, 2019
Renal monocyte chemoattractant protein-1: an emerging universal biomarker and therapeutic target for kidney diseases?Frederick W K Tam, Albert C M Ong
Expert Opinion on Biological Therapy|November 6, 2013
B-cell-targeted therapy in adult glomerulonephritisAnisha Tanna, Frederick W K Tam, Charles D Pusey
Purinergic Signalling|June 10, 2009
P2 receptors in renal pathophysiologyClare M Turner, James I Elliott, Frederick W K Tam
Nephron. Experimental Nephrology|May 25, 2011
Urine proteomics and biomarkers in renal diseaseMin Jeong Kim, Andrew H Frankel, Frederick W K Tam
Clinical Nephrology|July 14, 2012
P2 purinoceptors: Renal pathophysiology and therapeutic potentialJohn W R Booth, Frederick W K Tam, Robert J Unwin
Pageof 9

Showing results (1-10 of 87) with videos related to

Sort By:
Pageof 9
Expert Opinion on Investigational Drugs|October 17, 2006
Current pharmacotherapy for the treatment of crescentic glomerulonephritisFrederick W K Tam
Seminars in Nephrology|September 5, 2018
Role of the Spleen Tyrosine Kinase Pathway in Driving Inflammation in IgA NephropathyStephen McAdoo, Frederick W K Tam
Clinica Chimica Acta; International Journal of Clinical Chemistry|August 20, 2011
Urinary monocyte chemoattractant protein-1 in renal diseaseMin Jeong Kim, Frederick W K Tam
Drugs of the Future|January 4, 2013
Fostamatinib DisodiumStephen P McAdoo, Frederick W K Tam
Clinical Journal of the American Society of Nephrology : CJASN|December 15, 2017
TESTING Corticosteroids in IgA Nephropathy: A Continuing ChallengeFrederick W K Tam, Charles D Pusey
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 16, 2019
Renal monocyte chemoattractant protein-1: an emerging universal biomarker and therapeutic target for kidney diseases?Frederick W K Tam, Albert C M Ong
Expert Opinion on Biological Therapy|November 6, 2013
B-cell-targeted therapy in adult glomerulonephritisAnisha Tanna, Frederick W K Tam, Charles D Pusey
Purinergic Signalling|June 10, 2009
P2 receptors in renal pathophysiologyClare M Turner, James I Elliott, Frederick W K Tam
Nephron. Experimental Nephrology|May 25, 2011
Urine proteomics and biomarkers in renal diseaseMin Jeong Kim, Andrew H Frankel, Frederick W K Tam
Clinical Nephrology|July 14, 2012
P2 purinoceptors: Renal pathophysiology and therapeutic potentialJohn W R Booth, Frederick W K Tam, Robert J Unwin
Pageof 9